Lurasidone Pharmacokinetics in Chinese Psychiatric Inpatients: Impact of Valproate and Age

Ye Yang published a population pharmacokinetic model for lurasidone based on therapeutic drug monitoring data from 156 Chinese psychiatric inpatients, providing 212 serum concentration measurements. The study characterizes the impact of valproate co-medication and age on drug exposure, finding that valproate increases clearance by 47.7% and that most observed concentrations fell below the AGNP reference range. The dataset was last updated on May 12, 2026.

Use Cases

• Build predictive models for lurasidone exposure based on patient age and valproate co-medication status.
• Simulate concentration profiles for different patient subgroups using the established population pharmacokinetic model.
• Inform therapeutic drug monitoring interpretation by adjusting for covariates identified as significant.

Strengths

• Model developed from 212 serum concentration measurements from 156 patients.
• Identifies specific quantitative impacts: valproate co-administration increased apparent clearance by 47.7%.
• Includes model-based simulations stratified by age and valproate co-medication.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 13.5 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Routine therapeutic drug monitoring data analyzed using nonlinear mixed-effects modeling (NONMEM).

Freshness

Last updated 2026-05-12 05:26:56; freshness should be verified.

Geography

Chinese psychiatric inpatients.